Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 34 of 95, showing 5 Applications out of 471 total, starting on record 166, ending on 170

# Protocol No Study Title Investigator(s) & Site(s)

166.

ECCT/21/07/06   GBT132_Inclacumab-Ps 3 Trial
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Fredrick Asirwa Chite
2. Videlis N Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Strathmore University Medical Centre (Nairobi City county)
 
View

167.

ECCT/21/07/05   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa       
Principal Investigator(s)
1. Dr Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. KEMRI Walter Reed Project (Kericho county)
3. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

168.

ECCT/21/07/04   Healthy Route
    A Non-Interventional Pilot Study to Evaluate A Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate from Digital Retinal Images   
Principal Investigator(s)
1. Mansoor Noorali Saleh
2. Videlis Nduba
Site(s) in Kenya
1. Aga Khan University Hospital Clinical Research Unit (Nairobi City county)
2. Kenya Medical Research Institute CRDR (Nairobi City county)
 
View

169.

ECCT/21/07/03   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Prof Jessie N Githanga
2. Fredrick Sirwa Chite
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
View

170.

ECCT/21/07/02   TALIOS
    A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View